EcoBiotics has an experienced Board and Senior Management which provides an effective balance of business and scientific expertise. Our company is built around innovation and scientific excellence but we have a very clear focus on the commercialisation of our discoveries.

Our drug discovery program brings together expertise in natural product and synthetic chemistry, botany, ecology, cancer biology and microbiology.

To complement our research capabilites we also develop strategic R&D partnerships with businesses and institutions that have complementary skills and technologies to EcoBiotics.



Board & Senior Management

Victoria Gordon

Victoria Gordon, Ph.D.

Chairman & Chief Business Development Officer

Dr Victoria Gordon is co-founder and Chairman of EcoBiotics Limited.

Dr Gordon has held senior scientific and management positions in government and industry. She was Technology Director for one of Australia's largest companies with an integrated portfolio covering the natural resource, agribusiness and manufacturing sectors. She was also a Research Scientist with CSIRO (the Australian Federal Government's research agency) where she achieved widespread recognition for her work on chemical ecology in tropical rainforests.

Dr Gordon has a PhD in Microbiology, Bachelor of Applied Science (Hons.), Diplomas in Human and Animal Health and is a Graduate of the Australian Institute of Company Directors. She is a director of BioPharmaceuticals Australia Pty Ltd and of the Australian Rainforest Foundation (a not-for-profit private sector conservation organisation).

Paul Reddell

Paul Reddell, Ph.D.

Executive Director & Chief Executive Officer

Dr. Paul Reddell is co-founder and Chief Executive Officer of EcoBiotics Limited.

Dr Reddell has held senior scientific positions in government and industry, including as Principal Research Scientist for CSIRO (the Australian Federal Government's research agency) and as Principal Ecologist with the Rio Tinto group of companies. He has been an expert technical advisor to international agencies and private companies in the forestry and biotechnology sectors.

Dr. Reddell holds a PhD in Forest Ecology, a Bachelor of Science (1A Hons. Microbiology) and is a Fellow of the Australian Institute of Company Directors. He also serves as a member of the Australian Government's Gene Technology Technical Advisory Committee.

Graham Caldwell

Graham Caldwell

Non-Executive Director & Company Secretary

Mr Caldwell holds a Bachelor of Business (Accounting), is an associate member of CPA Australia, a Fellow of the Institute of Mangement, Member of the Institute of Chartered Accountants, Fellow of the Taxation Institute of Australia and is a Graduate Member of the Institute of Company Directors.

Mr Caldwell is a Director of a boutique consulting firm Fortis One and was previously a Business Consultant at WHK Cairns and was their Chief Executive. Mr Caldwell brings to EcoBiotics a broad knowledge of corporate finance and taxation and has extensive experience in business improvement, aquisitions, tax advice and planning, strategic planning and corporate change management. He specialises in providing guidance in relation to a wide range of business, taxation and financial matters across a diverse group of clients and industries.

Michael Wenzel

Michael Wenzel

Chief Financial Officer

Michael has a long history with the EcoBiotics Group, initially as manager of the KPMG financial auditing team and more recently as our Finance and Accounting Manager. Michael’s extensive experience with the group provides a sound background for the position as CFO.

Michael holds a Bachelor of Commerce, is a Registered Company Auditor, a Certified Internal Auditor and Member of the Institute of Internal Auditors – Australia and is an Associate of the Chartered Accountants Australia and New Zealand.

Michael has gained a wealth of experience across a range of industries, working for over 13 years in the audit and advisory divisions of KPMG Cairns.  During this time, Michael was a senior engagement manager, key client contact, and quality control reviewer on a variety of external and internal audits including biotechnology companies.

Michael specialises in the areas of Australian Accounting Standards, financial and management reporting matters and advisory services.


Scientific Advisory Committee

Professor Peter Parsons

Head, Drug Discovery Group,
Queensland Institute of Medical Research

Professor Peter Parsons is Senior Principal Research Fellow and head of the Drug Discovery Group at the Queensland Institute of Medical Research. His research interests are signalling pathways in tumor cells and novel therapies for cancer, including interpretation of pharmacogenomic profiles for anticancer agents, bioactivity-guided purification of natural products, and validation of drugs in tumor models in vivo.

Professor Parsons holds a PhD in organic chemistry from the University of Adelaide. After postdoctoral studies in the UK on biosynthesis of natural products he moved to the University of Queensland and later the Queensland Institute of Medical Research. He published some of the first evidence for anticancer efficacy of histone deacetylase inhibitors, and continues collaboration with medicinal chemists. His group played a major role in preclinical development and commercial manufacture of a skin cancer drug currently in clinical trials by Peplin Ltd.

A conjoint professor in the School of Medicine, the University of Queensland, Professor Parsons has published 190 papers, is co-author on 5 patents, supervises 3 postgraduate students, and is a member of 4 professional societies.


Dr Craig Williams

Laboratory Head, Synthetic Chemistry,
University of Queensland

Dr. Williams is a leader in natural products Total Synthesis Group located with the School of Chemistry and Molecular Biosciences at the University of Queensland. He is an organic chemist with a research focus oriented on the construction of very complex biologically active natural products. Targets and areas of expertise cover diterpenes, diterpene alkaloids, tetranortriterpenes, saturated and unsaturated nitrogen, oxygen and sulfur containing heterocycles.

Dr. Williams obtained a PH.D in synthetic organic chemistry from Flinders University (South Australia) under the supervision of Prof. Rolf. Prager. He held post-doctural appointments at the University of Gottingen in Germany (Prof. Armin de Meijere) and at the Australian National University in Canberra (Prof.Lewis N. Mander), before being appointed to the University of Queensland in 2000. Dr. Williams has worked with German Pharmaceutical company Bayer and with a number of Australian biotechnology companies on aspects of chemical synthesis. He has published more than 80 scientific papers, patents, review articles and book chapters.


R&D Partners

Strategic partnerships with R&D businesses and institutions with complementary skills and technologies to EcoBiotics is an important part of our business model.

These partnerships allow us to:

  • broaden the R&D expertise available to our company;
  • access world-class R&D facilities;
  • add further value to our products; and,
  • harness the scientific and commercial opportunities that arise from focused multi-disciplinary research teams.

Our current strategic R&D partners are:

  • The Queensland Institute of Medical Research
  • Department of Chemistry, University of Queensland